The new type 2 diabetes drug Trajenta (linagliptin 5 mg film-coated tablets) received Marketing Authorization from the European Commission for the treatment of type 2 diabetes. The European Commission has approved linagliptin in combination with metformin and metformin plus sulfonylurea. Linagliptin is also approved for use as monotherapy in patients… Read more
Results from a retrospective analysis of more than 778,000 patients showed the addition of Byetta (exenatide) injection to pre-existing diabetes treatment regimens was associated with a reduced likelihood of heart failure, especially among patients receiving insulin. These findings were presented by Amylin and Eli Lilly… Read more
Amylin, Eli Lilly and Alkermes, announced results from long-term extensions of the DURATION-1 and 3 studies evaluating Bydureon (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the… Read more
The European Medicines Agency’s (EMA) medicinal committee issued an opinion recommending the approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta in Europe) for the treatment of adults with type 2 diabetes. If adopted by the European Commission, the drug made and distributed by Eli Lilly and Boehringer Ingelheim, will be the only… Read more
The European Commission has granted marketing authorization to Eli Lilly, Amylin Pharmaceuticals and Alkermes’ type 2 diabetes drug Bydureon (exenatide extended-release for injectable suspension). Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist, and is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients… Read more
The new type 2 diabetes drug Tradjenta (linagliptin) is now available by prescription in pharmacies across the United States including Walgreens, CVS, Rite Aid following the U.S. Food and Drug Administration (FDA) approval of the drug on May 2, 2011. Tradjenta was approved as a prescription medication to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes… Read more
The U.S. Food and Drug Administration (FDA) approved Eli Lilly’s supplemental new drug application (sNDA) for Humalog(R) (insulin lispro injection [rDNA origin]).
Based on the updated label, people with type 1 diabetes using Humalog for pump therapy can use the insulin in the pump reservoir for up to seven days… Read more
U.S. District Court for the Southern District of California granted Amylin Pharmaceuticals a temporary restraining order (TRO) related to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement… Read more
Amylin Pharmaceuticals announced that it has filed a lawsuit against Eli Lilly. Amylin alleges Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements to maximize commercialization of exenatide currently marketed as BYETTA® (exenatide) injection… Read more
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim and Eli Lilly’s type 2 diabetes drug Tradjenta (linagliptin) as a medication used along with diet and exercise to lower blood sugar in adult patients.
The drug can be used as monotherapy or in combination with other commonly prescribed medications… Read more